Ophthalmologic Center of the Second Hospital, Jilin University, Ziqiang Street 218, Changchun, 130000, P.R. China.
Clinical College, Jilin University, Xinmin Street 70, Changchun, 130000, P.R. China.
Immunotherapy. 2022 Aug;14(12):985-994. doi: 10.2217/imt-2021-0303. Epub 2022 Jun 13.
Noninfectious uveitis is a common blinding eye disease, and an autoimmune response is involved in its pathogenesis. Biological agents have gradually been introduced into the treatment of noninfectious uveitis. The authors reviewed the clinical application and side effects of different biological agents on noninfectious uveitis. Biological agents that target TNF-α are widely used in the clinic. Other biological agents, such as IL-6- and IL-1-neutralizing antibodies, are used in patients who do not respond to TNF inhibitors. The efficacy of IL-17 neutralizing antibodies in noninfectious uveitis is controversial. Biological agents targeting T cells and signaling pathways provide new drug options for treatment of noninfectious uveitis. However, it cannot be ignored that these biological agents have side effects, such as increasing risk of infection.
非感染性葡萄膜炎是一种常见的致盲眼病，其发病机制涉及自身免疫反应。生物制剂已逐渐被引入非感染性葡萄膜炎的治疗中。作者综述了不同生物制剂在非感染性葡萄膜炎中的临床应用及不良反应。靶向 TNF-α 的生物制剂在临床上应用广泛，而对于 TNF 抑制剂治疗无效的患者则使用针对 IL-6 和 IL-1 的中和抗体等其他生物制剂。IL-17 中和抗体治疗非感染性葡萄膜炎的疗效存在争议。靶向 T 细胞及信号通路的生物制剂为非感染性葡萄膜炎的治疗提供了新的药物选择。但不容忽视的是，这些生物制剂存在增加感染风险等不良反应。
